Clinical effectiveness of CT-P13 (Infliximab biosimilar) used as a switch from Remicade (infliximab) in patients with established rheumatic disease. Report of clinical experience based on prospective observational data

Variations in criteria regulating treatment with reimbursed biologic DMARDs across European countries. Are differences related to country's wealth?

(2013) Polina Putrik et al.   ANNALS OF THE RHEUMATIC DISEASES

A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study

(2013) Dae Hyun Yoo et al.   ANNALS OF THE RHEUMATIC DISEASES

A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study

(2013) Won Park et al.   ANNALS OF THE RHEUMATIC DISEASES

MicroRNA-127-5p Regulates Matrix Metalloproteinase 13 Expression and Interleukin-1β-Induced Catabolic Effects in Human Chondrocytes

(2013) Su Jin Park et al.   ARTHRITIS AND RHEUMATISM

The role of biosimilars in the treatment of rheumatic diseases

(2012) Thomas Dörner et al.   ANNALS OF THE RHEUMATIC DISEASES

The economic pressures for biosimilar drug use in cancer medicine

(2012) Paul Cornes   Targeted Oncology

Disparities in rheumatoid arthritis disease activity according to gross domestic product in 25 countries in the QUEST-RA database

(2009) T Sokka et al.   ANNALS OF THE RHEUMATIC DISEASES